MORGAN STANLEY PLC/CALL/MODERNA/112.5/0.1/20.12.24 Share Price

Warrant

DE000MB7BPQ9

Market Closed - Börse Stuttgart 01:20:47 06/07/2024 am IST
2.17 EUR +0.46% Intraday chart for MORGAN STANLEY PLC/CALL/MODERNA/112.5/0.1/20.12.24
3 months+39.10%
6 months-11.07%
Date Price Change
05/24/05 2.17 +0.46%
04/24/04 2.16 +6.93%
03/24/03 2.02 -3.35%
02/24/02 2.09 +1.95%
01/24/01 2.05 -5.53%

Delayed Quote Börse Stuttgart

Last update July 06, 2024 at 01:20 am IST

More quotes

Static data

Product typeWarrants
Buy / SellCALL
Underlying MODERNA, INC.
Issuer Morgan Stanley
WKN MB7BPQ
ISINDE000MB7BPQ9
Date issued 12/06/2023
Strike 112.5 $
Maturity 20/12/2024 (167 Days)
Parity 10 : 1
Emission price 4.38
Emission volume N/A
Settlement règlement en espèces
Currency EUR

Technical Indicators

Highest since issue 6.01
Lowest since issue 0.55
Delta0.65x
Omega 3.241
Premium15.19x
Gearing4.97x
Moneyness 1.052
Difference Strike -5.82 $
Difference Strike %-5.17%
Spread 0.05
Spread %2.25%
Theoretical value 2.195
Implied Volatility 62.69 %
Total Loss Probability 51.41 %
Intrinsic value 0.5369
Present value 1.658
Break even 136.29 €
Theta-0.04x
Vega0.03x
Rho0.02x

Company Profile

Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows: - revenue from product sales (95.7%) ; - revenues from grants (4%); - revenues from collaboration agreements (0.3%). At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development. Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Sector
-
More about the company

Ratings for Moderna, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings

Consensus: Moderna, Inc.

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
24
Last Close Price
118.3 USD
Average target price
145.9 USD
Spread / Average Target
+23.27%
Consensus